FDA's Decade Of TNF Blocker Experience Eased Path For Simponi Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s first-cycle approval of Centocor’s TNF inhibitor Simponi (golimumab) encapsulates the double-edged position of late entrants into crowded drug classes: while differentiating a new product may pose a commercial challenge, FDA’s experience with early members of the class can smooth the way to approval for late-comers.
You may also be interested in...
Roche's Actemra Approved For RA After Year's Delay - To Craft A REMS?
Roche's novel interleukin-6 inhibitor Actemra won FDA approval Jan. 8 for second-line use in rheumatoid arthritis - after an FDA "complete response" letter set the product's regulatory process back more than a year
Roche's Actemra Approved For RA After Year's Delay - To Craft A REMS?
Roche's novel interleukin-6 inhibitor Actemra won FDA approval Jan. 8 for second-line use in rheumatoid arthritis - after an FDA "complete response" letter set the product's regulatory process back more than a year
Just-Approved Cimzia Set To Enter Tough RA Market
UCB vows to prove skeptics wrong with a swift, successful launch of pre-filled syringes.